DOT1L and acute myeloid leukemia: In addition to pinometostat, two new DOT1L inhibitors have recently been examined in vitro and in PDX mouse models of primary MLL-rearranged AML and demonstrated comparable responses as pinometostat, but a much-improved bioavailability after oral administration [165].